Lung cancer is the first cause of cancer death worldwide and the Hippo pathway transcriptional coactivators YAP/ TAZ have a pro-oncogenic role in this context. In order to understand the mechanisms through which YAP/TAZ elicit their oncogenic role in different systems, many studies are focused on YAP/TAZ target genes involved in the regulation of cell proliferation/survival and migration. However, there is scarce evidence on the role of YAP/TAZ in microRNA regulation while there is increasing evidence supporting the role of microRNAs in the main oncogenic processes. Here, we showed that YAP/TAZ were able to regulate several microRNAs in non-small cell lung cancer (NSCLC) cell lines. In detail, we focused on a cluster of three oncogenic microRNAs (miR-25, 93 and 106b) hosted in the MCM7 gene that were overexpressed in lung tumors compared to normal tissues. In addition, similar behavior was observed in breast cancer and head and neck tumor casuistries, where they showed a prognostic role. In NSCLC cells, YAP/TAZ induced the transcription of the MCM7 gene and its hosted miRs, thereby promoting cell proliferation through the posttranscriptional inhibition of the p21 cell cycle regulator. Accordingly, p21 was maintained at low levels in lung tumors compared to normal tissues. Conversely, its expression was restored in NSCLC cells upon YAP/TAZ interference or upon treatment with the statin cerivastatin. In summary, we provide evidence for a novel mechanism of modulation supporting the protumorigenic functions of the YAP/TAZ factors through the modulation of a bioncogenic locus consisting of one gene and three hosted microRNAs.
Introduction
Among solid tumors, lung cancer is the first cause of cancer death worldwide and ~16.8% of people in the USA diagnosed with lung cancer survive 5 years after the diagnosis (1) . One of the reasons for this short survival is the fact that most diagnoses are given when the cancer has already progressed beyond a localized state (2) . Approximately 80-85% of lung cancers are non-small cell lung cancer (NSCLC) (3) . YAP, the final target of the hippo signaling transduction pathway that controls organ size, development, tissue regeneration-homeostasis and stem cell self-renewal [reviewed in (4) ] has been shown to work as an oncogene in many solid cancers and it is upregulated or hyperactivated compared to normal tissue [reviewed in (5) ]. Moreover, higher YAP level or activity correlates with poorer prognosis and shorter patients survival. In that context, YAP transcriptionally activates genes involved in cell proliferation and migration [reviewed in (5) ]. Accordingly, in lung YAP overexpression has been associated with progression and poor prognosis of NSCLC (6, 7) . Similarly, TAZ, the homologous counterpart of YAP, has been shown as an oncogene in NSCLC (8) . Conversely, AMOT, a scaffold protein that sequesters YAP and TAZ into the cytoplasm inhibiting their nuclear function, decreases lung cancer progression (9) . Moreover, LATS2, a kinase that inhibits YAP/TAZ nuclear function, is frequently mutated in NSCLC (10) . In vivo mouse models showed that overexpression of constitutively active YAP was sufficient to drive lung tumor progression, while knockdown of YAP1 or TAZ decreased in vitro cellular migration and transplantation of metastatic disease (11) . Lists of YAP pro-oncogenic target genes have been published from studies on several different experimental mammalian systems and conditions (11) (12) (13) (14) (15) (16) (17) , but not in the context of human lung cancer. It is important to note that YAP binding profile genome-wide is very different in tumor cell lines compared to non-tranformed cells (18) .
Interestingly, two studies have been published on YAP regulated microRNAs in MCF10A cells (19) or in human pulmonary arterial adventitial fibroblasts (20) but there is scarce evidence in cancer cell lines or in the tumor context. Alterations in miRNA expression can contribute to tumor growth by inappropriately modulating critical genes involved in tumor cell proliferation, survival and migration. To elucidate the oncogenic role of YAP in the regulation of oncogenic microRNAs, we searched for microRNAs upregulated by YAP in lung cancer. We unravelled a YAP/TAZ dependent modulation of a bioncogenic locus consisting of one oncogenic gene and three intragenic microRNAs which strongly impinges on the main protumorigenic features of NSCLC cells.
Materials and methods

Cell culture, transfection and chemical treatment
Human H1299 and H1975 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and routinely tested by PCR for mycoplasma contamination by using the following primers: Myco_fw1: 5′-ACACCATGGGAGCTGGTAAT-3′, Myco_rev1: 5′-CTTCATCGACTTTCAG ACCCAAGGCA-3′. Cells were grown in RPMI medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum at 37°C in a balanced air humidified incubator with 5% CO2. Cells were transfected with Lipofectamine RNAimax (Invitrogen) in accordance with the manufacturer's instruction. siRNAs were used at the final amount of 300 pmol in 60 mm dish. LNA inhibitors for miR-25, 93 and 106b (Exiqon, Vedbaek, Denmark) were used at a final amount of 150 pmol in 60 mm dish. Cerivastatin (CER) was purchased from Sigma Aldrich. Cells were treated with dimethylsulphoxide (NT) as a negative control or 1 μM CER alone or with 0.5 mM mevalonate (MVA). Cells were collected 48 h after transfection or treatment with CER.
Stable transfection
H1299 cells were transfected using Lipofectamine® 2000 according to manufacturer instruction with a PIG/22 construct containing a 800-bp intronic sequence that functions as a precursor (pri-miR) of the miR-25, 93 and 106b cluster (PIG-MIR), or with the empty vector as a control (PIG-EV) (21) . 24 h after transfection, cells were diluted at 20-30% confluency and fresh medium with 3 μg/μl puromicine was added for selection of stably transfected cells every 3-4 days. Cells were selected for 10-15 days and then they were grown in fresh medium containing 1 μg/μl puromicine, tested for correct miRs overexpression and expanded. For all experiments, cells were maintained in fresh medium containing 1 μg/μl puromicine.
Clonogenic assay
Cells were transfected as indicated above and 24-48 h later they were detached and seeded at 500-1000 cells/well into six-well dishes (COSTAR). Fresh medium was added every 4 days. Colonies were stained with crystal violet and counted after 7-14 days.
FACS cell cycle analysis
For cell cycle analysis, cells were collected 48 h after interference or LNA treatment and fixed in 70% ethanol overnight. Fixed cells were treated with RNase at 1 mg/ml final concentration for 30 min at 37°C or overnight at 4°C before adding 5 mg/ml PI and analyzed with Guava Easycyte 8HT flow cytometer equipped with Guava Soft 2.1 (Millipore).
Protein extracts and Western blot analysis
Cells were lysed in buffer with 50 mM Tris-HCl pH 7.6, 0.15 M NaCl, 5 mM EDTA, 1% Triton X-100 and fresh protease inhibitors. Extracts were sonicated for 10 + 15 s and centrifuged at 12 000× rpm for 10 min to remove cell debris. Protein concentrations were determined by colorimetric assay (Bio-Rad). Western blotting was performed using the following primary antibodies: rabbit polyclonal anti YAP (Santa Cruz, sc-15407), rabbit polyclonal anti TAZ (Sigma anti-WWTR1, HPA007415), mouse monoclonal anti B-actin (ACTBD11B7, Santa Cruz, sc-81178), rabbit monoclonal anti MCM7 (D10A11, Cell Signaling, 3735S), mouse monoclonal anti-TEF-1 (BD-Transduction Laboratories, 610 923), rabbit monoclonal anti-p21 Waf1/Cip1 (Cell Signaling, 2947S), rabbit polyclonal anti Phospho-YAP Ser127 (Cell Signaling, 4911), mouse monoclonal anti-HSP90 (Santa Cruz, sc-13 119), and rabbit polyclonal anti-p21 (Santa Cruz, sc-397).
Secondary antibodies used were goat anti-mouse and goat antirabbit, conjugated to horseradish peroxidase (Amersham Biosciences, Piscataway, NJ).
MiRNA microarray analysis
The analyses were performed by hybridization on Agilent microarrays of RNA preparations from three independent biological replicates. Briefly, RNA was extracted with TRIZOL and purified using the miRNAeasy® kit (Qiagen, Chatsworth, CA) following the manufacturer's instructions. The concentration and purity of total RNA were assessed using a Nanodrop TM 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE). Total RNA (100 ng) was labeled with miRNA Hybridization kit (Agilent Technologies) according to manufacturer instructions and hybridized to Human miRNA Microarray V19 (Agilent Technologies). Scanning and image analysis were performed using the Agilent DNA Microarray Scanner (P/N G2565BA) equipped with extended dynamic range (XDR) software according to the Agilent miRNA Microarray System with miRNA Complete Labeling and Hyb Kit Protocol manual. Feature Extraction Software (Version 10.5) was used for data extraction from raw microarray image files using the miRNA_107_Sep09_1_1_QC protocol. A Z-score transformation was performed to express the background corrected spot intensity values as a unit of standard deviation from the normalized mean of zero. Features were selected based on Z-ratios calculated as the difference between the averages of the observed miRNA's Z-scores divided by the standard deviation of all the differences of the comparison. Absolute Z-ratios higher than 1.5 were inferred as significant. Deregulated miRNAs were used for hierarchical clustering (see also Supplementary Tables S1a and b, available at Carcinogenesis Online). 
MiRNA and transcript analysis
ChIp analysis
ChIP-qPCR was performed as described previously in (16) . Briefly, cells were fixed with 1% formaldehyde (Sigma) in culture medium for 10 min at room temperature, and chromatin from lysed nuclei was sheared to 200-600 bp fragments using a Bioruptor sonicator (Diagenode 
Luciferase assay
For Luciferase assay, H1299 or H1975 cells were cotransfected in 24-well dishes using Lipofectamine 3000 (Invitrogen) with 100 ng of pGL3-Basic containing a p21 Waf1/Cip1 3′ UTR-firefly luciferase reporter (a kind gift of Dr. Arnold Gruenweller, Philipps-Marburg University, 35 032 Marburg, Germany), the same vector with a 3bp deletion in the seed sequence recognized by miR-25, 93 and 106b or pGL3 empty vector as a control, plus 10 ng of the transfection control Renilla vector (pRLTK, Promega), and the LNA Negative Control or LNA inhibitor for miR-25, 93 and 106b at a final amount of 25 pmol/well. Cells were harvested 24-48 h posttransfection and luciferase activities were analyzed by the dual-luciferase reporter assay system (Promega, Madison, WI) in the GloMax 96 Microplate Luminometer (Promega). Mutagenesis was performed through QuikChange II Site-Directed Mutagenesis Kit (Agilent technologies) following the manufacturer's instructions and using the nucleotides listed below: del61-63-antisense: 5′-cttcatttgtctaccgaacttccccggagtgg-3′; del61-63-sense: 5′-gaagtaaacagatggcttgaaggggcctcacc-3′. Correct deletion was confirmed by plasmid generation.
Sequence of siRNA used for interference
siGFP (as non-silencing control) 5′-AAGUUCAGCGUGUCCGGGGAG-3′, siYAP#1: 5′-GACAUCUUCUGGUCAGAGA-3′, siYAP#2: 5′-CUGGUCAGAG AUACUUCUU-3′, siTAZ#1: 5′-AAAGUUCCUAAGUCAACGU-3′, siTAZ#2: 5′-AGGUACUUCCUCAAUCACA-3′, siMCM7#1: 5′-UACUACGAGGG AUAUUUCCUU-3′, siMCM7#2: 5′-GAUCACACGAGGCUUGUUGUU-3′, siLATS1: 5′-CAUACGAGUCAAUCAGUAA-3′, siLATS2: 5′-GCCACGACUUA UUCUGGAA-3′, siTEAD1#1: 5′-CGAUUUGUAUACCGAAUAA-3′, siTEAD1#2: 5′-GAAAGGUGGCUUAAAGGAA-3′.
Sequence of primers used for transcript analyses
RT-MCM7-F: 5′-TCGAGGCATGAAAATCCGGG-3′, RT-MCM7-R: 5′-CGCCAGTCG ATCAATGTATGACA-3′, RT-YAP-F:5′-CACAGCATGTTCGAGCTCAT-3′, RT-YAP-R:
5′-GATGCTGAGCTGTGGGTGTA-3′, RT-TAZ-F: 5′-CCATCACTAATAATAGCTCAGATC-3′, RT-TAZ-R: 5′-GTGATTACAGCCAGG TTAGAAAG-3′, RT-TEAD1-F: 5′-CCACCAAAGTTTGCTCCTTTGGGA-3′, RT-TEAD1-R: 5′-ACTTCAAACACACAGGCCATGCAG-3′, RT-LATS1-F: 5′-CTCTG CACTGGCTTCAGATG-3′;
RT-LATS1-R, 5′-TCCGCTCTAATGGCTTCAGT-3′, RT-LATS2-F: 5′-ACATTCACTGGTGGGGACTC-3′, RT-LATS2-R: 5′-GTGGGAGT AGGTGCCAAAAA-3′;
RT-GAPDH-F 5′-GAGTCAACGGATTTGGTCGT-3′, RT-GAPDH-R:
5′-GACAAGCTTCCCGTTCTCAG-3′, RT-premiR25-F: 5′-GTGTTGAGAGGGCGGAGACTT-3′;
RT-premir25-R:
5′-CTCGGGAAGTGCTAGCTCA-3′, RT-premiR106b-F:
Sequence of primers used for ChIp
ChIP-CTGF-F:
5′-CTTTGGAGAGTTTCAAGAGCC-3′; ChIP-CTGF-R: 5′-TCTGTCCACTGACATACATCC-3′; ChIP-MCM7enh-F: 5′-CAGAACTCGGA TTAGGGCTG-3′; ChIP-MCM7enh-R: 5′-GCT TGGGAAGTGAGTCAAAACT-3′; ChIP-H1H2BA-F: 5′-ACTCTCCTTACGGGTCCTCTTG-3′; ChIP-H1H2BA-R-AGTGCTGTGTAACCCTGGAAAA.
Differentially expressed miRNAs or genes
Deregulation of miRNAs or genes in different set of patient samples was assessed by two tailed student's t test, and a false discovery rate procedure was performed to take into account multiple comparisons. Significance level was set to 5%. Analyses were performed by Matlab (The MathWorks Inc.).
Curves of recurrence free survival
Curves of recurrence free survival in HN patients were evaluated by Kaplan-Meier method. The expression levels of the samples were sorted to obtain three subgroups with high, medium or low signal for each miRNA. Curves of patients with high and low signals were considered to establish statistical significance by using the logrank test. Calculation of the miRNA score signature was obtained as described in (22) . Analyses were performed by Matlab (The MathWorks Inc.). (Supplementary Table 1a and b, available at Carcinogenesis Online). Among them, miR-130b-3p, miR-29a-3p, miR-29b-3p and miR-29c-3p result regulated by YAP in agreement with recent reports (19, 20) (Supplementary Figure 1b , available at Carcinogenesis Online). We focused our attention on miR-25-3p, miR-93-5p and miR-106b-5p that belong to an intragenic cluster (named microRNA-106b-25 cluster) located in intron 13 of Minichromosome Maintenance complex 7 (MCM7) gene (Figure 1a) (21) . These are oncogenic microRNAs that induce both cell proliferation and migration and are overexpressed in several tumors together with the MCM7 host gene (23) (24) (25) (26) . Moreover, MCM7 has been shown to be an important prognostic marker in lung cancer (27) (28) (29) . MCM7 is a member of a family of DNA helicases important for initiating DNA replication and for cell cycle progression (30) . In H1299 cells depleted of YAP protein, we confirmed that miR-25, 93 and 106b expression decreased and further observed a reduction in the MCM7 mRNA level (Figure 1b ). This result is paired with two previous studies where MCM7 was shown to be upregulated upon YAP or TAZ overexpression in MCF10A cells (13, 31) and with a recent work where MCM7 has been shown to be a YAP/TAZ transcriptional target in breast cancer cell lines by ChIP-seq (see below) (16) .
Results
MCM7
Downregulation of YAP/TAZ, MCM7 and miR-25, 93 and 106b affects cell proliferation in NSCLC
YAP was shown to work redundantly with TAZ in several model systems (16, 32) . In agreement with this, we observed that simultaneous knockdown of YAP and TAZ synergistically affected colony forming ability in H1299 cells (Figure 1c; Supplementary Figure 1d Data points were generated from the average of at least three independent biological replicates. SEM is indicated. Asterisks represent statistically relevant results calculated using Two-tailed t test. P and n values: miR-25 siYAP#1/siGFP P = 0.003 n = 6, miR-93 siYAP#1/siGFP P = 0.04 n = 3, miR-106b siYAP#1/siGFP P = 0.02 n = 3, MCM7 106b at a final amount of 150 pmol in 60 mm dish. Data are presented as mean ± SEM. Two-tailed t test analysis was applied to calculate the P values. H1299 siYAP#2/ siGFP P = 0.05 n = 3, siTAZ#1/siGFP P = 0.02, n = 3, si TAZ#2/siGFP P = 0.01, n = 3, siYAP#1TAZ#1/siGFP P = 0.001 n = 3, siYAP#2TAZ#2/siGFP P = 0.007 n = 3, siMCM7#1/ siGFP P = 6.69 × 10 −5 n = 3, siMCM7#2/siGFP P = 0.002 n = 3. H1975 siYAP#1/siGFP P = 0.03 n = 3, siYAP#2/siGFP P = 0.006 n = 3, siTAZ#1/siGFP P = 0.005 n = 3, siTAZ#2/siGFP P = 0.006 n = 3, siYAP#1TAZ#1/siGFP P = 2.8 × 10 −13 n = 3, siYAP#2TAZ#2/siGFP P = 1.2 × 10 −5 n = 3, siMCM7#1/siGFP P = 0.002 n = 3, siMCM7#2/siGFP P = 9.8 × 10 −6 n = 3. H1299 LNAmiR-25/ctrl P = 0.002 n = 3, LNAmiR-2593106b/ctrl P = 0.003 n = 3, H1975 LNAmiR-25/ctrl P = 0.006 n = 3, LNAmiR-93/ctrl P = 0.02 n = 3, LNAmiR-106b/ctrl P = 0.05 n = 3, LNA miR-2 593 106b/ctrl P = 0.001 n = 3. Figure 1f and g, available at Carcinogenesis Online). Interestingly, either siRNAs-mediated downregulation of MCM7 or LNAs mediated inhibition of miR-25, 93 and 106b strongly phenocopied the effect of YAP/TAZ interference in both cell lines (Figure 1d , f, g and h; Supplementary Figure 1h -m, available at Carcinogenesis Online).
YAP, TAZ and TEAD regulate the expression of MCM7 gene and its hosted microRNA cluster
As mentioned above, Zanconato et al. showed that YAP and TAZ regulated several cell cycle related genes, among those MCM7. In detail by performing ChIP-seq experiments and integrating their data with previously reported high-resolution maps of chromatin interactions (Hi-C), the authors observed the binding of YAP/ TAZ to a distal enhancer that interacts with the MCM7 promoter in a breast cancer cell line (16) (Figure 2a ). In the latter context, YAP/TAZ cooperated with the TEAD transcription factors that are often associated with YAP/TAZ in the upregulation of their oncogenic targets (13, 31) . To explain in detail the abovementioned observations and to match them with our findings, we assessed the levels of the miR-25, 93 and 106b precursors (pre-microRNA) siYAP#1TAZ#1/siGFP P = 0.001 n = 6, siYAP#2TAZ#2/siGFP P = 0.002 n = 3, pre-miR-93 siYAP#1TAZ#1/siGFP P = 0.007 n = 6, siYAP#2TAZ#2/siGFP P = 0.004 n = 3, pre-miR-106b siYAP#1TAZ#1/siGFP P = 0.01 n = 6, siYAP#2TAZ#2/siGFP P = 0.009 n = 3, MCM7 siYAP#1TAZ#1/siGFP P = 0.004 n = 3, siYAP#2TAZ#2/siGFP P = 0.01 n = 3. H1975 pre-miR-25 siYAP#1TAZ#1/siGFP P = 0.004 n = 3, siYAP#2TAZ#2/siGFP P = 0.009 n = 4, pre-miR-93 siYAP#1TAZ#1/siGFP P = 0.01 n = 3, siYAP#2TAZ#2/siGFP P = 0.003 n = 3, pre-miR-106b siYAP#1TAZ#1/siGFP P = 0.02 n = 3, siYAP#2TAZ#2/siGFP P = 0.007 n = 3, MCM7 siYAP#1TAZ#1/siGFP P = 0.004 n = 3, siYAP#2TAZ#2/siGFP P = 0.003 n = 3.
in the YAP/TAZ siRNA-transfected H1299 and H1975 cells. We observed that YAP/TAZ interference induced a significative downregulation of MCM7 transcript and hosted miR precursors with two alternative siRNAs (Figure 2b and c; Supplementary   Figure 1n and o, available at Carcinogenesis Online). Moreover, we observed that the TEAD1 transcription factor was involved in the regulation of the mature miRNAs, their precursors and their host gene MCM7 (Figure 3a and b; Supplementary Figure 2a and pre-miR-93 siTEAD#1/siGFP P = 0.01 n = 4, siYAP#1TEAD1#1/siGFP P = 0.04 n = 4, pre-miR-106b siTEAD#1/siGFP P = 0.01 n = 4, siYAP#1TEAD1#1/siGFP P = 0.01 n = 4, MCM7 siYAP#1TEAD1#1/siGFP P = 0.02 n = 4. H1975 P and n values: pre-miR-25 siTEAD#1/siGFP P = 0.01 n = 3, siYAP#1TEAD1#1/siGFP P = 0.006 n = 4, pre-miR-93 siTEAD#1/siGFP P = 0.02 n = 4, siYAP#1TEAD1#1/siGFP P = 0.008 n = 4, pre-miR-106b siYAP#1TEAD1#1/siGFP P = 0.02 n = 4, MCM7 siYAP#1TEAD#1/siGFP P = 0.01 n = 4. (C, D) Quantification by real time-PCR of YAP, TEAD1, CTGF and ANKRD1 transcript level, normalized to GAPDH, in H1299 (C) and H1975 (D) cells. All experiments have been performed at least in triplicate. SEM is indicated. H1299 P and n values: YAP siYAP#1TEAD#1/siGFP P = 3.6 × 10 −5 n = 5, TEAD1 siTEAD#1/siGFP P = 6.2 × 10 −6 n = 5, siYAP#1TEAD#1/ siGFP P = 2.6 × 10 −7 n = 5, CTGF siTEAD#1/siGFP P = 0.03 n = 9, siYAP#1TEAD1#1/siGFP P = 8.9 × 10 6 n = 9, ANKRD1 siTEAD1#1/siGFP P = 0.01 n = 6, siYAP#1TEAD1#1/siGFP P = 5.8 × 10 −7 n = 7. H1975 P and n values: YAP siYAP#1TEAD1#1/siGFP P = 0.002 n = 4, TEAD1 siTEAD#1/siGFP P = 0.003 n = 3, siYAP#1TEAD#1/siGFP P = 9.5 × 10 −6 n = 4, CTGF siTEAD#1/siGFP P = 0.01 n = 3, siYAP#1TEAD1#1/siGFP P = 0.001 n = 4, ANKRD1 siTEAD#1/siGFP P = 0.04 n = 4, siYAP#1TEAD1#1/siGFP P = 0.01 n = 4. (E, F) ChIP-qPCR performed on the promoter of YAP direct target CTGF (13) and on MCM7 enhancer found as a YAP/TAZ target in (16) . CTGF promoter and MCM7 enhancer sequences were enriched in YAP-immunoprecipitated chromatin (grey) but not in negative control IP (IgG, black) or in immunoprecipitated chromatin obtained from YAP-depleted cells. Moreover, YAP binding was not detected on negative control (H1H2BA, promoter of histone H2B type 1-A). Charts are relative to a representative experiment for each cell line. Two-tailed t test analysis was applied to calculate the P values. H1299 CTGF prom: siGFP-αIGG/siGFP-αYAP: P = 0.03; siGFP-αYAP/siYAP-αYAP: P = 0.004; MCM7 enhancer: siGFP-αIGG/siGFP-αYAP: P = 0.001; siGFP-αYAP/siYAP-αYAP: P = 0.002. H1975: CTGF prom: siGFP-αIGG/siGFP-αYAP: P = 0.001; siGFP-αYAP/siYAP#1-αYAP: P = 0.03; MCM7 enhancer: siGFP-αIGG/siGFP-αYAP: p=00 006 siGFP-αYAP/siYAP#1-αYAP: P = 0.005.
b, available at Carcinogenesis Online). In addition, we observed a stronger effect when TEAD1 and YAP were simultaneously depleted. As control, we analyzed the mRNA abundance of two well-known YAP/TAZ transcriptional targets, CTGF and ANKRD1 whose levels were expectedly reduced upon YAP/TAZ and TEAD interference in both cell lines (Figure 3c Interestingly, two recent reports showed that YAP/TAZ activity is controlled by the MVA metabolic pathway. The geranylgeranyl pyrophosphate, an intermediate of the MVA cascade, is required for activation of Rho GTPases that, in turn, inhibits YAP/ TAZ phosphorylation thus promoting their nuclear accumulation. Treatment of different cell lines with statins, inhibitors of the upstream steps of this pathway, caused TAZ degradation and YAP/TAZ hyperphosphorylation and translocation from the nucleus to the cytoplasm, thus inhibiting their nuclear function in transcriptional activation of pro-oncogenic genes and reducing tumor growth in mice xenograft (33) (34) (35) .
We treated H1299 cells with the statin CER in order to check whether we could recapitulate the effects observed upon YAP/TAZ interference. Upon CER treatment, we observed an increased phosphorylation of YAP and decreased TAZ level confirming previous results (33) (Supplementary Figure 3c, available at Carcinogenesis Online, left panel). Strikingly, we observed a reduction in MCM7 protein and transcript, while concomitant treatment with MVA reversed CER effect (Supplementary Figure 3c , available at Carcinogenesis Online, left and right panels). Finally, we performed chromatin immunoprecipitation analysis (ChIP) in both H1299 and H1975 and we observed the binding of YAP onto the enhancer region regulating MCM7 gene (Figure 3e and f) . Together, these results strongly suggest that the MCM7 locus behaves as a canonical Hippo pathway target.
YAP/TAZ and TEAD lower p21 expression through MCM7 and its hosted microRNAs
In silico analysis of The Cancer Genome Atlas (TCGA) revealed that a high expression of the miR-25, 93, 106b and of the MCM7 mRNA was significantly enriched within lung cancer tissues as opposed to normal tissues (Figure 4a ). In addition, coordinated enrichment for the mentioned miRNAs in the tumor tissues was observed in a breast cancer casuistry and in a head and neck tumor casuistry previously studied by our group (22, 36) ( Supplementary Figure 4a and b, available at Carcinogenesis Online, upper panels, Supplementary Table 2, available at Carcinogenesis Online). Further, in the analyzed head and neck cancer patients, we observed a higher recurrence probability in patients overexpressing miR-25, 93 and 106b (Supplementary Figure 4b , available at Carcinogenesis Online, lower panels).
In order to address the oncogenic role of YAP/TAZ exerted through the regulation of miR-106b-25 cluster, we searched for transcripts anti-correlated to miR-25, 93 and 106b in the TCGA lung cancer and that could be bona fide targets of at least one of these miRNAs as calculated by three different prediction softwares (Supplementary Tables 3 and 4 , available at Carcinogenesis Online, sheet 1). This could provide information about potential targets that might be clinically relevant in lung cancer. Pathway enrichment analysis and functional classification of the obtained transcripts list with DAVID functional annotation (37, 38) revealed that the identified genes belonged mainly to focal adhesion, siYAP/TEAD1 H1299 cells respect to control counterparts. SEM is indicated. Asterisks represent statistically relevant results. P and n values: p21 siYAP#1/siGFP P = 0.005 n = 9; siTAZ#1/siGFP P = 0.03 n=3; si YAP#1TAZ#1/siGFP P =0.004 n = 6; siTEAD1#1/siGFP P = 0.03 n = 6; siYAP#1TEAD1#1/siGFP P = 0.01 n = 5. (C, D) As described in Figures   (A, B) but for the H1975 cell line. SEM is indicated. P and n values: p21 siYAP#1/siGFP P = 0.01 n = 7; siTAZ#1/siGFP P = 0.002 n = 6; siYAP#1TAZ#1/siGFP P = 0.006 n = 5; siTEAD1#1/siGFP P = 0.02 n = 4; siYAP#1TEAD1#1/siGFP P = 0.01 n = 4. (E) Schematic representation of different mechanisms through which YAP/TAZ may regulate p21 protein abundance as shown in previous works (left and right panels (39, 40) ) and as shown in our study (mid panel).
calcium signaling and cancer pathways (Supplementary Table 4 , available at Carcinogenesis Online, sheets 2 and 3, Figure 4b ). We focused on this latter category and in particular on CDKN1A (Cyclin-Dependent Kinase inhibitor 1A) encoding for the p21 protein, also known as p21WAF1/Cip1, a negative regulator of the cell cycle (Supplementary Table 4 , available at Carcinogenesis Online, sheet 2, Supplementary Figure 4c , available at Carcinogenesis Online). We chose CDKN1A for several reasons:
1. It has already been shown to be a target of miR-93 and miR-106b (23) . To further validate this in our system, H1299 and H1975 cells co-transfected with the pGL3 plasmid containing p21-3′UTR cloned downstream the firefly luciferase gene along with LNA inhibitors for miR-25, 93 and 106b showed a higher firefly luciferase signal compared to cells co-transfected with the same vector and with control LNA. This effect was abrogated when the p21-3′UTR was Figure 6c , available at Carcinogenesis Online). The effect of miR-25, 93 and 106b overexpression in reducing p21 protein accumulation upon YAP/TAZ and MCM7 interference is clear. However, the biological effect of the overexpression of this miR cluster on cell cycle distribution is rather mild. This might also be due because YAP/TAZ and MCM7 affect several different pathways that converge to modulate important cell cycle regulators like p21 protein, while miR-25, 93 and 106b cluster is only a piece of the puzzle contributing to this effect together with other several players.
Discussion
In this work, we provide an example of how YAP and TAZ can elicit their oncogenic function by employing both transcriptional and post-transcriptional mechanisms, through the simultaneous upregulation of the oncogenic MCM7 gene and its three hosted miR-25, 93 and 106b (Figure 6g ). Our findings extend current knowledge on the role of YAP/TAZ in microRNA abundance regulation in addition to the previously characterized role of YAP/TAZ in post-transcriptional microRNA processing through the modulation of Dicer and p72 microprocessor activity (43, 44) . Interestingly, the MCM7 gene locus in mice has been defined as a bi-oncogenic locus because both MCM7 protein and hosted miRNAs together (and not singularly) were required for cellular transformation and for initiating prostate tumorigenesis. In the latter work, miR-25, 93 and 106b were shown to exert their oncogenic role in part by regulating PTEN abundance (21) . In our study, these miRNAs do not strongly affect PTEN level, probably because other feedback mechanisms may prevent the alteration of its abundance (data not shown). However, these miRNAs regulate other important genes involved in oncogenic processes, one of which is p21 (Figure 6e and f). Moreover, it is likely that the reduction of MCM7 protein level independently of hosted miRs can have an impact on p21 abundance and cell cycle progression from G1 to S phase, because it has been already shown that alterations in MCM7 protein level (both for excess or deprivation) can activate cell cycle checkpoint (43, 44) . Downregulation of p21 abundance by YAP/TAZ through an indirect mechanism mediated by both MCM7 gene and hosted microRNAs may happen concomitantly with the other proposed transcriptional mechanisms (Figure 5e , mid panel). This is an example of how several distinct mechanisms orchestrated by YAP/TAZ converge to modulate important cell cycle regulators whose abundance needs to be finely tuned in the cell and whose dysregulation provides the targeted cells with protumorigenic properties. It is likely that other YAP/TAZ targets may act as codingindependent players in regulating oncogenic processes in addition to microRNAs. For example, competing endogenous RNA, long non coding RNA, enhancer associated RNA are emerging for their role in development and cancer beyond the direct transcriptional regulation of genes (45) (46) (47) (48) . In favor of this hypothesis, recently YAP and TAZ have been mapped at enhancers much more frequently than in proximity of transcription start sites (16) . It will be interesting in the future to deeply characterize these potential targets. Importantly, treatment of NSCLC cells with statin phenocopies what observed upon YAP/TAZ interference. This reinforces previous experimental evidences in mouse tumor models and epidemiological data in humans showing tumor suppressing effects of statins (49, 50) and further strengthens the concept that statins may be promising therapeutic inhibitors of YAP/TAZ oncogenic activity (33, 34) .
A deeper understanding and analysis of the multiple layers regulating oncogenic mechanisms could be relevant for the characterization of novel prognostic factors in cancer and for the development of novel anticancer therapies.
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